Azadyne Ltd

📍 Canterbury, United Kingdom🗓 Founded 2016👥 2 employees💰 Last funded 2019
Pharmaceutical Manufacturing🌐 Azadyne.com
Website LinkedIn
We are a pharma R&D company dedicated to delivering improved medicines for patients with autoimmune disease, including Multiple Sclerosis. AZADYNE originated from cutting-edge research from the laboratories of Profs Vincent P. Kelly, Stephen Connon and J. Mike Southern of Trinity Biomedical Sciences Institute, Trinity College Dublin. Autoimmunity occurs when the body mistakenly attacks itself resulting in inflammation and damage. Over time this can lead to chronic, debilitating diseases such as Multiple Sclerosis, Rheumatoid Arthritis and Inflammatory Bowel Disease. Currently, these diseases are not curable. Our pioneering approach has identified a naturally occurring micronutrient called queuine with the ability to control autoimmune response in the body. Through novel chemistry and unique insights, AZADYNE has developed new molecules delivering improved therapeutic outcomes for patients and their families. Our candidates are on the path to Phase I or FIH trials.
1
Total investors
0
Early stage
1
Mid stage
0
Late stage
2016
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Azadyne Ltd?
Azadyne Ltd has 1 investors on record on gritt.io, 1 mid-stage.
When did Azadyne Ltd last raise funding?
The most recent investment in Azadyne Ltd recorded on gritt.io was in 2019.
When was Azadyne Ltd founded?
Azadyne Ltd was founded in 2016.
What industry is Azadyne Ltd in?
Azadyne Ltd operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Azadyne Ltd based?
Azadyne Ltd is headquartered in Canterbury, United Kingdom.